Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics and absorption, distribution, metabolism and excretion profiling of tanimilast following an intravenous C-microtracer coadministered with an inhaled dose in healthy male individuals.
Drug Metab Dispos
January 2025
Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Tanimilast is an inhaled phosphodiesterase-4 inhibitor currently in phase III clinical development for treating chronic obstructive pulmonary disease and asthma. This trial aimed to characterize the pharmacokinetics, mass balance, and metabolite profiling of tanimilast. Eight healthy male volunteers received a single dose of nonradiolabeled tanimilast via powder inhaler (Chiesi NEXThaler [3200 μg]), followed by a concomitant intravenous infusion of a microtracer ([C]-tanimilast: 18.
View Article and Find Full Text PDFHarnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review.
Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Queen Rania Street, Al Jubeiha, Amman, 11942 Jordan.
Background this systematic review was conducted to assess the practical application of terbium radioisotopes, utilizing systematic search methodologies to identify relevant studies. Methods the databases of PubMed, Web of Science, and Scopus were systematically scoured, targeting the research on four terbium isotopes: Tb, Tb, Tb, and Tb. Various combinations of keywords related to terbium and its four radioisotopes were used in the search process.
View Article and Find Full Text PDF[Measurement of Airborne Radioactivity in the Inpatient Room after Administering [Cu]Cu-ATSM to Patients].
Kaku Igaku
January 2025
Department of Radiology, Kindai University Faculty of Medicine.
Objective: [Cu]Cu-ATSM is a radiotherapeutics under clinical trials. It is necessary to take appropriate measures to limit its exposure and ensures its airborne concentrations do not exceed legally permitted levels. Therefore, the purpose of this study was to measure the airborne radioactivity concentration in the inpatient room after administering [Cu]Cu-ATSM to patients.
View Article and Find Full Text PDFTowards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics.
Angew Chem Int Ed Engl
January 2025
Oak Ridge National Laboratory, Chemical Sciences Division, UNITED STATES OF AMERICA.
Antimony-119 (119Sb) is one of the most attractive Auger-electron emitters identified to date, but it remains practically unexplored for targeted radiotherapy because no chelators have been identified to stably bind this metalloid in vivo. In a departure from current studies focused on chelator development for Sb(III), we explore the chelation chemistry of Sb(V) using the tris-catecholate ligand TREN-CAM. Through a combination of radiolabeling, spectroscopic, solid-state, and computational studies, the radiochemistry and structural chemistry of TREN-CAM with 1XX/natSb(V) were established.
View Article and Find Full Text PDFEffectiveness and safety of radionuclide synovectomy with Yttrium-90 hydroxyapatite in patients with inflammatory arthritis: a longitudinal study.
Nucl Med Commun
January 2025
Department of Pharmacology.
Background And Objective: Yttrium-90 plays a significant role in managing drug-resistant inflammatory arthritis through radionuclide synovectomy, where the radioisotope is injected into the affected joint to alleviate pain and inflammation by targeting the synovial tissue. This study aims to evaluate the effectiveness and safety of Yttrium-90 hydroxyapatite radionuclide synovectomy in improving joint functionality, as judged by physicians, in patients with inflammatory arthritis who had not responded to conventional treatments.
Methods: Patients with inflammatory arthritis were recruited from the orthopedics department and referred to the nuclear medicine department for evaluation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!